JW Therapeutics Presents JWCAR201 Clinical Study Data at Hematology Conference
I'm PortAI, I can summarize articles.
JW Therapeutics presented updated data from its Investigator-Initiated Trial of JWCAR201, a CAR-T product targeting CD19/CD20, at the 67th American Society of Hematology Annual Meeting. The study, conducted in China, evaluated the safety and preliminary efficacy of JWCAR201. This information was originally published by JW Cayman Therapeutics via the Hong Kong Stock Exchange's Issuer Information Service.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments